EVSA-T（人乳腺癌細(xì)胞）
CBP60367
詢 價
索取STR
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫
| I. General information | |
| Synonyms: | EVSA-T |
| Background: | established from the malignant ascitic effusion from a woman with metastatic breast carcinoma; described as being estrogen receptor-negative and progesterone receptor-positive |
| Species: | human (Homo sapiens) |
| Tissue: | breast |
| Disease: | breast carcinoma |
| Gender: | N/A |
| Morphology: | adherent epitheloid cells growing in monolayers; |
| Growth Mode: | N/A |
| Doubling Time: | ca. 50 hours |
| DNA Profile: | N/A Our Cell Line Authentication Service |
| Culture Medium: |
MEM + 10% FBS+ 1% Non Essential Amino Acids (NEAA) + 1mM Sodium Pyruvate (NaP) EVSA-T完全培養(yǎng)基，# CBP60367M |
| Cryopreservation medium: | 90%FBS+10%DMSO |
| Mycoplasma: | contamination was eliminated with Ciprobay (ciprofloxacin), then negative in DAPI, microbiological culture, RNA hybridization, PCR assays |
| Immunology: | cytokeratin +, cytokeratin-7 +, cytokeratin-8 +, cytokeratin-17, cytokeratin-18 +, cytokeratin-19 +, desmin -, endothel -, EpCAM +, GFAP -, neurofilament -, vimentin - |
| Fingerprint: | multiplex PCR of minisatellite markers revealed a unique DNA profile |
| Species: | confirmed as human with IEF of AST, MDH, NP |
| Cytogenetics: | human hypotriploid karyotype with 4% polyploidy - 62(55-64)<3n>XXX, +1, -2, -5, -5, +6, -8, -9, -10, -13, -13, -14, -15, -16, -17, -18, -20, -22, +6-8mar, add(X)(p11), der(X)t(X;9)(q21;q11), add(1)(p1?1), der(1)del(1)(p36)dup(1)(q22q32), del(1)(q11), der(1;4)(q10;q10)del(4)(q1?13q?23), der(2)t(2;5)(p11;q13)add(2)(q3?5), der(3)t(3;5)(p14;q11), del(4)(q22), del(6)(q25q27), del(6)(p11), add(6)(p23), del(7)(p14), add(8)(q24), ider(8)(q10)ins(8;?)dup(8)(?q21q24)add(8)(q24), add(11)(p15), add(12)(p13), del(12)(p13), dup(13)(q21q33), add(21)(p11), add(21)(p11), large submetacentric der(8) hsr marker present |
| Virus | ELISA: reverse transcriptase negative; PCR: EBV -, HBV -, HCV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV +, SMRV - |
| Comments: | For more information, please contact us (4008-750-250). |
